铅笔束扫描质子放疗作为食管癌三联疗法组成部分的前瞻性初步研究
这项前瞻性初步研究计划纳入30例适合放化疗后行食管切除术的局部晚期食管或胃食管交界癌患者,评估铅笔束扫描质子放疗在三联疗法中的安全性和疗效。主要终点为归因于放化疗的急性3级及以上不良事件,发生率为30%,最常见的为白细胞减少和中性粒细胞减少。5年总生存率为46%,无进展生存率为39%。
要点
- 急性3级及以上不良事件发生率为30%,非血液学急性3级及以上不良事件发生率为3%。
- 90%的患者接受了食管切除术,R0切除率为93%,病理完全缓解率为40%。
- 5年总生存率为46%,无进展生存率为39%,局部区域复发率为17%,远处转移率为40%。
核心结论
- 铅笔束扫描质子放疗作为食管癌三联疗法的组成部分是可行且安全的。
研究设计与样本
- 前瞻性初步研究,计划纳入30例医学上适合放化疗后行食管切除术的局部晚期食管或胃食管交界癌患者。
- 质子放疗方案为25次,肿瘤加1厘米范围给予50 Gy,黏膜外扩3.5厘米及区域淋巴结给予45 Gy。
- 化疗包括每周卡铂(曲线下面积2 mg/mL/min)和紫杉醇(50 mg/m2)。
主要发现
- 2015年6月至2017年4月共入组30例合格患者,中位年龄68岁,腺癌占87%,远端食管/胃食管交界占90%,T3至T4期占87%,N1至N3期占80%。
- 所有患者均完成计划放疗剂量,急性3级及以上不良事件发生率为30%,最常见的为白细胞减少和中性粒细胞减少,急性3级及以上非血液学不良事件发生率为3%。
- 90%的患者接受了食管切除术(R0切除率93%),病理完全缓解率为40%,术后主要并发症(Clavien-Dindo评分≥3)发生率为34%,术后30天死亡率为3.7%。
- 中位随访5.2年,5年总生存率为46%,无进展生存率为39%,局部区域复发率为17%,远处转移率为40%。
- 癌症治疗功能评估-食管量表评分(中位数)在基线、放化疗结束时、食管切除术前、12个月和24个月分别为145、136(与基线相比p=0.0002)、144、146和157。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and efficacy of pencil beam scanning (PBS) proton radiation therapy (RT) in trimodality therapy for esophageal cancer. METHODS AND MATERIALS: This prospective pilot study was planned to accrue 30 patients with locally advanced esophageal or gastroesophageal junction carcinoma medically suitable for chemoradiation therapy (CRT) followed by esophagectomy. PBS proton RT consisted of 25 fractions, 50 Gy to tumor + 1 cm and 45 Gy to a 3.5 cm mucosal expansion and regional lymph nodes. Chemotherapy included weekly carboplatin (area under the curve, 2 mg/mL/min) and paclitaxel (50 mg/m2). At 4 to 8 weeks after CRT, patients underwent restaging and potential esophagectomy. The primary endpoint was acute grade 3+ adverse events (AEs) attributed to CRT. Overall survival and progression-free survival were assessed using the Kaplan-Meier methodology; local-regional recurrence and distant metastases rates were assessed using the cumulative incidence methodology. The Functional Assessment of Cancer Therapy-Esophagus assessed quality of life. RESULTS: Thirty eligible patients were enrolled from June 2015 to April 2017. Median age was 68 years. Histology was adenocarcinoma in 87%, and location was distal esophagus/gastroesophageal junction in 90%. Stage was T3 to T4 in 87% and N1 to N3 in 80%. All patients completed the planned RT dose. Acute grade 3+ AEs occurred in 30%, most commonly leukopenia and neutropenia. Acute grade 3+ nonhematologic AEs occurred in 3%. Esophagectomy was performed in 90% of patients (R0 in 93%). Pathologic complete response rate was 40%. Major postoperative complications (Clavien-Dindo score, ≥3) occurred in 34%. Postoperative mortality at 30 days was 3.7%. Median follow-up was 5.2 years. Five-year outcome estimates were overall survival at 46%, progression-free survival at 39%, local-regional recurrence at 17%, and distant metastases at 40%. Functional Assessment of Cancer Therapy-Esophagus scores (medians) at baseline, at the end of CRT, before esophagectomy, at 12 months, and at 24 months were 145, 136 (p = .0002 vs baseline), 144, 146 and 157, respectively. CONCLUSIONS: PBS proton RT is feasible and safe as a component of trimodality therapy for esophageal cancer.
引用
- Hallemeier CL, Merrell KW, Neben-Wittich MA, et al. A Prospective Pilot Study of Pencil Beam Scanning Proton Radiation Therapy as a Component of Trimodality Therapy for Esophageal Cancer. Adv Radiat Oncol. 2024. PMID: 39081847. doi:10.1016/j.adro.2024.101547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。